MIKHAIL BLAGOSKLONNY ADVANCEMENT IN CANCER TREATMENT

Mikhail Blagosklonny is a renowned scientist who focuses mainly on aging and cancer disease. He graduated from the First Pavlov State Medical University of St Petersburg in Russia with an MD in Internal Medicine. His voracious studies saw him earning a Ph.D. in the same university. This university is one of the best medical schools in Russia and among top ten in Europe. It produces medical professionals of renowned stature on dovepress.com.

In 2002, Prof. Mikhail was appointed at New York Medical College as an associate professor before joining Ordway Research Institute as a senior scientist on ncbi.nlm.nih.gov. He retained this position till he moved to Roswell Park Cancer Institute as the professor of oncology.

Mikhail scientific works on Oncotarget focus on how cancer treatment can be carried out without interfering with normal cells integrity. Besides, he proposes that the anti-cancer drug- Rapamycin is used as a possible life-extending drug. This proposal is likely from the fact that the mechanistic Target of Rapamycin (mTOR) has biological effects on insulin, growth factors and amino acids. Also, mTOR senses the levels of nutrient, energy, and oxygen. The ultimate result of mTOR is the regulation of the function of mammalian tissues like liver, white and brown adipose tissue, muscles and brains.

Mikhail has proved that Rapamycin has beneficial effects like life extension in mammals. Studies carried out shows that high mTOR signaling is healthy in young age. This high level is unsuitable in old age. Rapamycin acts by blocking this increase thus prolonging life span.

Initiation and development of cancerous cells are associated with high activation of mTOR. This activation results in increased protein synthesis resulting in more cell growth and proliferation published on Oncotarget. The effect of Rapamycin is by blocking this mTOR activation lowering the spread of cancerous cells in various body organs.

Mikhail is involved in several editorial activities. He is the chief editor in Aging Cell Cycle and Oncotarget. Also, he is an associate editor of Cancer Biology & Therapy. Besides, Mikhail has published over 270 papers in peer-reviewed journals Oncotarget.

Oncotarget publishing has earned him h-index 83.An h-index calculates the number of times a publication is cited in other papers.